Positron Emission Tomography/Magnetic Resonance Imaging in Patients
This clinical trial studies positron emission tomography (PET)/magnetic resonance imaging (MRI) in patients undergoing PET/computed tomography (CT). Diagnostic procedures, such as PET/MRI, may help doctors diagnose cancer or help doctors predict a patient's response to treatment
Checked against the public recordLast updated Feb 24, 2020 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Case Comprehensive Cancer Center
- Interventions being studied
- Device: magnetic resonance imaging with positron emission tomography scanning
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Only patients who are referred by their physician to have a clinical PET/CT will be eligible to participate in the study * we propose to obtain a second PET/MRI on 100 patients after their clinical PET/CT imaging that spans several disease categories and includes the following cancers: lung, colon, melanoma, head/neck and lymphoma * In addition to oncology patients, we anticipate imaging a subset of non-cancer patients who will also be imaged subsequent to their clinical PET/CT who will be referrals from neurology and cardiology * All subjects will be at least 18 years old, or if under 18, parents or guardians must give consent * Subjects must be stable and have experienced no adverse events from previous clinical PET/CT examination Exclusion Criteria: * Subjects who do not meet the above inclusion criteria * Subjects unwilling or unable to sign the informed consent form * Subjects who are cognitively impaired and thus unable to give informed consent * Subjects unable to undergo MRI scanning due to exclusion via University Hospital Case Medical Center (UHCMC) MRI restrictions (e.g. implanted metallic or electronic devices, hip or other joint replacements, history of kidney disease, unacceptable creatinine or glomerular filtration rate \[GFR\], etc) * Patients who are pregnant
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University Hospitals Seidman Cancer Center, Case Comprehensive Cancer CenterCleveland, Ohio
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 24, 2020. Always confirm current availability with the study team.